Fosså S D
Norwegian Radium Hospital, Oslo.
Acta Urol Belg. 1994 Apr;62(1):73-6.
No systemic therapy has led to prolongation of life in patients with hormone resistant prostate cancer though secondary hormone treatment and chemotherapy have resulted in an about 30% response rate. The main goal of treatment is palliation and improvement of quality of life, the former aim obtained in 50-70% of the patients by radiotherapy of skeletal metastases. The evaluation of response, today assisted by the use of prostate specific antigen, and the understanding of hormone resistance remain principal topics of clinical research in hormone resistant prostate cancer.
尽管二线激素治疗和化疗已产生约30%的缓解率，但尚无全身治疗能延长激素抵抗性前列腺癌患者的生命。治疗的主要目标是缓解症状和提高生活质量，通过对骨转移灶进行放射治疗，50%-70%的患者可实现前一目标。目前，在前列腺特异性抗原的辅助下进行疗效评估以及对激素抵抗的认识，仍然是激素抵抗性前列腺癌临床研究的主要课题。
